home   |   contact us   |   sitemap     

   about Formula Pharmaceuticals  technology  pipeline NewsCareers  
Top News


Media Contact  




May 5, 2016

Formula Pharmaceuticals appoints Malcolm K. Brenner, MD, PhD to its Scientific Advisory Board

Berwyn, PA – May 5, 2016 – Formula Pharmaceuticals, Inc. (“Formula”) today announced the appointment of Dr. Malcolm K. Brenner, Founding Director of the Center for Cell and Gene Therapy at Baylor College of Medicine, as a member of its Scientific Advisory Board (SAB). The SAB serves as a strategic resource to Formula as it continues to develop Chimeric Antigen Receptor (CAR) immunotherapies leveraging Cytokine Induced Killer (C.I.K.) cells targeting cancer and autoimmune disease.

“We are very excited to work with Dr. Malcolm Brenner, whose is a world leading expert in genetically modified T cells for cancer immunotherapy”, said Maurits W. Geerlings, President and CEO of Formula Pharmaceuticals. “Dr. Brenner’s invaluable insights in translational and molecular medicine will help us maximize the therapeutic potential within our C.I.K. CAR™ technology platform and drug candidates,” Dr. Geerlings added. Dr. Brenner will join fellow members of Formula’s SAB, Dr. David Scheinberg at Memorial Sloan Kettering Cancer Center, Dr. Robert Negrin at Stanford University, and Dr. Katy Rezvani at MD Anderson Cancer Center.

Malcolm Brenner is a professor in the departments of Pediatrics and Medicine, Section of Hematology-Oncology at Baylor College of Medicine. He is also the Founding Director of the Center for Cell and Gene Therapy at Baylor College of Medicine, The Methodist Hospital and Texas Children’s Hospital.

Dr. Brenner was Editor in Chief of Molecular Therapy and Associate Editor of Blood and he is the principal investigator or co-investigator on National Institutes of Health grants. Malcolm earned his Ph.D., M.B.Ch.B. and B.A. from Cambridge University in England. He is a Fellow of the Royal College of Pathologists and the Royal College of Physicians.

“The thought leaders assembled to Formula’s SAB bring together a first-class team of world leaders in cancer and autoimmune disease,” said Dr. Brenner. “I am honored to work alongside this group of experts and look forward to advancing Formula’s approach to CAR immunotherapy to benefit patients.”

About Formula Pharmaceuticals. Inc.

Formula Pharmaceuticals is a privately held, immuno-oncology focused company located in Berwyn, Pennsylvania focused on the development of CAR immunotherapy for oncology and autoimmune diseases. Formula’s technology platform offers important opportunities for improvements to existing CAR approaches, with the objective to significantly increase patient access, clinical benefit potential, and cost-effectiveness of manufacturing. Formula plans to develop proprietary and licensed targets in hematologic oncology and solid tumor indications on its own and in partnership with others.
For more information, visit www.formulapharma.com.

Media Contact:
Mike Beyer
Sam Brown Inc.